Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Welsh

Showing results (271-280 of 329) with videos related to

Pageof 33
Sort By:
The Lancet. Diabetes & Endocrinology|February 29, 2024
5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension studyMichael Ej Lean, Wilma S Leslie, Alison C Barnes, et al.
BMJ Open Diabetes Research & Care|August 6, 2021
Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screeningJana J Anderson, Paul Welsh, Frederick K Ho, et al.
Journal of Alzheimer'S Disease : JAD|July 12, 2020
Alzheimer's Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769)Amy C Ferguson, Rachana Tank, Laura M Lyall, et al.
Cardiovascular Research|October 14, 2020
High sodium intake, glomerular hyperfiltration, and protein catabolism in patients with essential hypertensionGiacomo Rossitto, Giuseppe Maiolino, Silvia Lerco, et al.
European Journal of Heart Failure|September 30, 2017
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF studyPaul Welsh, Lei Kou, Changhong Yu, et al.
Plos Medicine|June 26, 2009
Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?Naveed Sattar, Heather M Murray, Paul Welsh, et al.
BMC Medicine|November 10, 2020
Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK BiobankFanny Petermann-Rocha, Peter Hanlon, Stuart R Gray, et al.
Plos Medicine|November 26, 2024
Routine measurement of cardiometabolic disease risk factors in primary care in England before, during, and after the COVID-19 pandemic: A population-based cohort studyFrederick K Ho, Caroline Dale, Mehrdad A Mizani, et al.
JAMA|August 23, 2012
Lipid-modifying therapies and risk of pancreatitis: a meta-analysisDavid Preiss, Matti J Tikkanen, Paul Welsh, et al.
JAMA Cardiology|June 4, 2025
Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical TrialKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
Pageof 33

Showing results (271-280 of 329) with videos related to

Sort By:
Pageof 33
The Lancet. Diabetes & Endocrinology|February 29, 2024
5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension studyMichael Ej Lean, Wilma S Leslie, Alison C Barnes, et al.
BMJ Open Diabetes Research & Care|August 6, 2021
Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screeningJana J Anderson, Paul Welsh, Frederick K Ho, et al.
Journal of Alzheimer'S Disease : JAD|July 12, 2020
Alzheimer's Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769)Amy C Ferguson, Rachana Tank, Laura M Lyall, et al.
Cardiovascular Research|October 14, 2020
High sodium intake, glomerular hyperfiltration, and protein catabolism in patients with essential hypertensionGiacomo Rossitto, Giuseppe Maiolino, Silvia Lerco, et al.
European Journal of Heart Failure|September 30, 2017
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF studyPaul Welsh, Lei Kou, Changhong Yu, et al.
Plos Medicine|June 26, 2009
Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?Naveed Sattar, Heather M Murray, Paul Welsh, et al.
BMC Medicine|November 10, 2020
Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK BiobankFanny Petermann-Rocha, Peter Hanlon, Stuart R Gray, et al.
Plos Medicine|November 26, 2024
Routine measurement of cardiometabolic disease risk factors in primary care in England before, during, and after the COVID-19 pandemic: A population-based cohort studyFrederick K Ho, Caroline Dale, Mehrdad A Mizani, et al.
JAMA|August 23, 2012
Lipid-modifying therapies and risk of pancreatitis: a meta-analysisDavid Preiss, Matti J Tikkanen, Paul Welsh, et al.
JAMA Cardiology|June 4, 2025
Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical TrialKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
Pageof 33